Eli Lilly's stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound.

Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click ...

Eli Lilly on Thursday posted better-than-expected quarterly results, but CVS Health's decision to drop the company's obesity ...

Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo ...

CVS said it will expand access to blockbuster weight loss drug Wegovy for patients covered by its pharmacy benefit manager, Caremark.

This marks a shift in its approach to treating the global obesity problem. Read more at straitstimes.com. Read more at ...

LLY has delivered impressive returns of 15% year-to-date (as of April 30), outperforming the S&P 500’s 5% decline during the ...

Sometimes, it makes sense to skip insurance and instead take advantage of a health savings account or flexible savings ...

She suggested I start taking the GLP-1 Zepbound through weekly injections, along with incorporating a healthy diet and ...

Eli Lilly said sales of weight loss drug Zepbound and diabetes treatment Mounjaro surged in the first quarter.

Viking is developing what might be a game-changing medication in the segment.

Eli Lilly and Company (NYSE: LLY) today announced its financial results for the first-quarter of 2025.